Real-world duvelisib study for non-Hodgkin lymphoma after relapse
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study looks at how duvelisib works in real life for adults with non-Hodgkin lymphoma that has come back or progressed after standard chemotherapy. Researchers also check whether participants can safely take the medicine and complete follow-up visits.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re an adult (18 or older) and can sign consent and follow the visit plan
- You have a confirmed non-Hodgkin lymphoma type such as follicular lymphoma, CLL/SLL, marginal zone lymphoma, peripheral T-cell lymphoma, or diffuse large B-cell lymphoma
- Your lymphoma has relapsed or progressed after at least one chemotherapy treatment
- Your blood counts and organ tests (liver/kidney) are adequate, and you’re not too weak (ECOG 0 to 2)
- Any current infection is treated first and must be under control before starting
- You are not pregnant or breastfeeding
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two targeted drugs, Chidamide and Duvalisib, for people with peripheral T-cell lymphoma or NK/T-cell lymphoma that has come back or not responded to previous treatment. The goal is to see if this drug combination can help shrink or control the lymphoma.
This trial tests a new drug, DZD8586, against other standard treatments for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that has come back or stopped responding to prior therapy. The goal is to see if DZD8586 works better or has fewer side effects.
This study tests whether taking two pills—zanubrutinib and lenalidomide—after finishing chemotherapy can help keep your DLBCL from coming back. It’s for patients who are already in complete remission after treatment.
This trial is testing a new combination of drugs for people with a high-risk type of lymphoma called DLBCL who have not been treated before. It adds loncastuximab and roflumilast to the standard R-CHOP therapy to see if it works better at fighting the cancer.
This trial tests whether the drug duvelisib can help keep T-cell lymphoma in remission after initial chemotherapy. It is for people who have finished first-line treatment with a CHOP-like regimen, achieved a complete response, and cannot or choose not to have a stem cell transplant.
This trial tests a new drug, duvelisib, against two standard chemotherapy drugs (gemcitabine or bendamustine) for people with T-cell lymphoma that has come back or not responded to treatment. Duvelisib is a targeted therapy that may work differently than chemotherapy.
Hear when a new Follicular Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.